Icanbelimod S1p receptor agonist 1|cas:1514888-56-2|西域试剂

Icanbelimod S1p receptor agonist 1,99.95%

产品编号：Bellancom-101265| CAS NO：1514888-56-2| 分子式：C₂₃H₂₄FN₃O₃| 分子量：409.45

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-101265	￥500.00	杭州北京（现货）
Bellancom-101265	￥2000.00	杭州北京（现货）
Bellancom-101265	￥3500.00	杭州北京（现货）
Bellancom-101265	￥11000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Icanbelimod S1p receptor agonist 1

产品介绍

Icanbelimod (S1p receptor agonist 1) 是一种有效的口服活性 S1P?receptor 激动剂，具有诱导 S1P1 内化的活性 (EC₅₀=9.83 nM)。Icanbelimod 有潜力用于研究关节炎和 EAE (实验性自身免疫性脑炎) 的相关研究。Icanbelimod 是专利 WO2015039587A1 中的化合物 2。

生物活性

Icanbelimod (S1p receptor agonist 1) is a potent and orally active?S1P?receptor agonist, exhibits an activity of inducing S1P1 internalization (EC₅₀=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). Icanbelimod is extracted from patent WO2015039587A1, Compound 2.

体外研究

体内研究

Icanbelimod (oral administration; 0.01 mg/kg-1 mg/kg) at all dose is active, and only a dose of 0.01 mg/kg is required to observe a decrease in the number of peripheral blood lymphocytes by more than 50% and a decrease in the 1 mg/kg dose. Besides, this compound is lymphocyte-specific, which dose not significantly alter the number of peripheral monocytes and other white blood cells in SD rats.
Icanbelimod (oral administration; 3 mg/kg; 12 days) is has been proved to block lymphocyte efflux. In the development of type II collagen-induced arthritis in rat model, compound 2 is effective in inhibiting the development of joint swelling in arthritis and joint structure destruction.
Icanbelimod (oral administration; 0.3-1mg/kg; 30 days; once daily) inhibits the development of experimental autoimmune encephalitis (EAE) as a dose-dependent manner in mice model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Lewis rats
Dosage:	3 mg/kg
Administration:	Oral administration
Result:	Decreased the severity score of arthritis in the four-legged rats.

Animal Model:	Female C57BL/6 mice
Dosage:	0.03, 0.1, and 1 mg/kg
Administration:	Oral administration
Result:	Decreased the severity score of EAE in MOG 35-55 induced mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Lewis rats
Dosage:	3 mg/kg
Administration:	Oral administration
Result:	Decreased the severity score of arthritis in the four-legged rats.

Animal Model:	Female C57BL/6 mice
Dosage:	0.03, 0.1, and 1 mg/kg
Administration:	Oral administration
Result:	Decreased the severity score of EAE in MOG 35-55 induced mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 6.8 mg/mL (16.61 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4423 mL	12.2115 mL	24.4230 mL
5 mM	0.4885 mL	2.4423 mL	4.8846 mL
10 mM	0.2442 mL	1.2212 mL	2.4423 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式